Magnesium L-threonate, Magtein, earns novel food authorization in the European Union

Photo © AdobeStock.com/Aleksander

AIDP has announced that its magnesium L-threonate ingredient, Magtein, has been authorized as a novel food in the European Union (EU). According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years, starting from November 7, 2024. That is unless a subsequent applicant obtains authorization without reference to the protected proprietary data used by AIDP in its novel food application. Additionally, under this exclusivity, AIDP and ThreoTech will have to approve the marketing of other magnesium L-threonate as novel foods. That means that companies wishing to market magnesium L-threonate during the exclusive period will have to get a license from ThreoTech and source the ingredient from them.

The law firm, Herbert Smith Freehills, has been retained to pursue companies in the EU that infringe upon the exclusivity granted by the novel food approval. “Novel food authorization for Magtein means EU consumers can now, for the first time, experience the clinically proven benefits that are unique to magnesium L-threonate,” said Edward Lee, ThreoTech CEO, in a press release. “In addition, the five-year period of exclusivity granted to AIDP, and its licensee ThreoTech, offers added reassurance to consumers, manufacturers, and brands that the magnesium L-threonate sourced through ThreoTech is guaranteed to be safe, authentic, and of the highest quality.”